Frankfurt - Delayed Quote • EUR
Nuformix plc (1RT.F)
As of 8:23 AM GMT+2. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Daniel John Gooding | Executive Director | 34.9k | -- | 1973 |
| Dr. Joanne M. Holland | Consultant | 76.79k | -- | 1975 |
| Mr. Benjamin Harber | Company Secretary | -- | -- | -- |
Nuformix plc
60 Gracechurch Street
6th Floor
London, EC3V 0HR
United Kingdom
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Corporate Governance
Nuformix plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available